Skip to main content
رجوع
MDGL logo

Madrigal Pharmaceuticals, Inc.

جودة البيانات: 100%
MDGL
NASDAQ Healthcare Biotechnology
KWD 445.04
▼ KWD 2.68 (-0.60%)
القيمة السوقية: 10.21B
نطاق اليوم
KWD 438.42 KWD 449.14
نطاق 52 أسبوعًا
KWD 265.00 KWD 615.00
حجم التداول
197,756
متوسط 50 يوم / 200 يوم
KWD 468.57 / KWD 437.29
الإغلاق السابق
KWD 447.72

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -35.4 0.3
P/B 16.9 2.9
ROE % -42.5 3.7
Net Margin % -30.1 3.8
Rev Growth 5Y % 10.0
D/E 0.6 0.2

السعر المستهدف للمحللين

Hold
KWD 705.670 +58.6%
Low: KWD 527.000 High: KWD 964.000
ربحية السهم المستقبلية
-KWD 4.488
الإيرادات المقدّرة
1.5 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 70.330
KWD 59.581 – KWD 79.312
4.9 B 4
FY2029 KWD 49.530
KWD 41.959 – KWD 55.855
3.9 B 4
FY2028 KWD 31.371
KWD 16.070 – KWD 49.150
3 B 11

النقاط الرئيسية

Negative free cash flow of -190.02M
Capital efficient — spends only 0.05% of revenue on capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)432.05%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-42.49%
ROIC-23.52%
Net Margin-30.08%
Op. Margin-31.31%

الأمان

Debt / Equity
0.59
Current Ratio4.01
Interest Coverage-13.45

التقييم

P/E Ratio
-35.41
P/B Ratio16.94
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 432.05% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 958.40M Net Income (TTM) -288.28M
ROE -42.49% ROA -22.89%
Gross Margin 94.14% Operating Margin -31.31%
Net Margin -30.08% Free Cash Flow (TTM) -190.02M
ROIC -23.52% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.59 Current Ratio 4.01
Interest Coverage -13.45 Dividend Yield 0.00%
Valuation
P/E Ratio -35.41 P/B Ratio 16.94
P/S Ratio 10.65 PEG Ratio 1.10
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 10.21B Enterprise Value 10.36B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 958.40M 180.13M 0.0 0.0 0.0
Net Income -288.28M -465.89M -373.63M -295.35M -241.85M
EPS (Diluted) -12.85 -21.90 -19.99 -17.23 -14.63
Gross Profit 902.26M 173.90M 0.0 0.0 0.0
Operating Income -300.10M -497.88M -380.50M -293.57M -242.48M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.26B 1.04B 640.55M 362.57M 273.33M
Total Liabilities 656.90M 287.86M 235.21M 165.18M 77.23M
Shareholders' Equity 602.69M 754.38M 405.33M 197.39M 196.11M
Total Debt 354.36M 119.57M 117.19M 49.89M 797,000.0
Cash & Equivalents 198.69M 100.02M 99.92M 331.55M 36.27M
Current Assets 1.25B 1.03B 637.28M 361.37M 271.68M
Current Liabilities 310.29M 169.28M 118.55M 115.89M 76.84M